Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

By D. Black, D. Thompson, D. Bauer, K. Ensrud, T. Musliner, M. Hochberg, M. Nevitt, S. Suryawanshi, Steve Cummings. Journal of Clinical Endocrinology and Metabolism, 2000

1,021 citations recorded by the source corpus.

Subfields: Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/a5d0fbb6d41bea8842bae6680b36d26453f9aa4c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Nelson B. Watts
2. S. Teitelbaum
3. R. Russell

In Orthopedics and Sports Medicine

1. Nelson B. Watts
2. S. Teitelbaum
3. R. Russell

Citations in the corpus

• Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014, background): “Alendronate reduces the incidence of spine and hip fractures by about 50 % over 3 years in patients with a prior vertebral fracture or in patients who have osteoporosis at the hip site [49, 59].”
• Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy (2008, methodology): “A nonvertebral fracture reduction within 6 to 12 months is also observed with risedronate as shown in a post-hoc analysis [135].”
• Severely suppressed bone turnover: a potential complication of alendronate therapy. (2005, background): “9 64/F GIO (fibromyalgia) 4 Prednisone, Ca, D Metatarsal, proximal femur (3) 8 months (proximal femur) Yes (3)”